A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)

Exclusion Criteria

• •Pregnant women, women who were breast feeding, or who believed they may have wished to become pregnant during the course of the study
• •Males and females of reproductive potential unwilling to use an effective method of contraception during the study
• •Decompensated liver disease defined as direct (conjugated) bilirubin \> 1.2 x ULN, prothrombin time \> 1.2 x ULN, platelets \< 150,000/mm\^3, serum albumin \< 3.5 g/dL, or prior history of clinical hepatic decompensation (eg, ascites, jaundice, encephalopathy, or variceal hemorrhage)
• •Received interferon (pegylated or not) therapy within 6 months of the screening visit
• •Alpha-fetoprotein \> 50 ng/mL
• •Evidence of hepatocellular carcinoma
• •Coinfection with hepatitis C virus (by serology), HIV, or hepatitis D virus
• •Significant renal, cardiovascular, pulmonary, or neurological disease
• •Received solid organ or bone marrow transplantation
• •Was currently receiving therapy with immunomodulators (eg, corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents susceptible of modifying renal excretion
• •Had proximal tubulopathy
• •Known hypersensitivity to the study drugs, the metabolites, or formulation excipients